Boehringer-话题@MedSci - 梅斯（MedSci）

#Boehringer#

7篇内容 | 915人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2039505, encodeId=de132039505d7, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=Boehringer收购AMAL公司，获得其针对晚期结直肠癌的肿瘤疫苗, objectType=article, longId=175749, objectId=dff21e5749a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dff21e5749a6, replyNumber=0, likeNumber=76, createdTime=2020-05-10, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dff21e5749a6, moduleTitle=Boehringer收购AMAL公司，获得其针对晚期结直肠癌的肿瘤疫苗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dff21e5749a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039504, encodeId=ae5a2039504c5, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, objectType=article, longId=174741, objectId=97ed1e4741da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ed1e4741da, replyNumber=0, likeNumber=93, createdTime=2020-01-05, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ed1e4741da, moduleTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=97ed1e4741da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039503, encodeId=fbb52039503a6, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=1期临床证实，Boehringer Ingelheim的白细胞介素-36单抗BI 655139可显著改善全身脓疱性银屑病, objectType=article, longId=161938, objectId=c4a4161938a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a4161938a0, replyNumber=0, likeNumber=65, createdTime=2019-12-14, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a4161938a0, moduleTitle=1期临床证实，Boehringer Ingelheim的白细胞介素-36单抗BI 655139可显著改善全身脓疱性银屑病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4a4161938a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, objectType=article, longId=141739, objectId=e257141e399a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e257141e399a, replyNumber=0, likeNumber=100, createdTime=2018-12-26, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e257141e399a, moduleTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e257141e399a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039501, encodeId=a47e20395010d, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=FDA承诺加快对Boehringer肺部疾病药物审批, objectType=article, longId=37481, objectId=cee73e48133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cee73e48133, replyNumber=0, likeNumber=56, createdTime=2014-12-13, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cee73e48133, moduleTitle=FDA承诺加快对Boehringer肺部疾病药物审批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cee73e48133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039500, encodeId=b2a120395000c, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=Boehringer开发抗凝血剂解毒剂获FDA突破性药物认证, objectType=article, longId=37142, objectId=63703e14274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63703e14274, replyNumber=0, likeNumber=60, createdTime=2015-02-19, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63703e14274, moduleTitle=Boehringer开发抗凝血剂解毒剂获FDA突破性药物认证, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=63703e14274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039499, encodeId=1bc0203949962, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, objectTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, objectType=article, longId=20862, objectId=c4442086208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4442086208, replyNumber=0, likeNumber=93, createdTime=2013-07-19, rootId=0, userName=12498fa0m11暂无昵称, userId=278f2500221, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4442086208, moduleTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4442086208)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Boehringer

2020-05-29

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

Boehringer收购AMAL公司，获得其针对晚期结直肠癌的肿瘤疫苗

2020-05-10

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂

2020-01-05

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

1期临床证实，Boehringer Ingelheim的白细胞介素-36单抗BI 655139可显著改善全身脓疱性银屑病

2019-12-14

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果

2018-12-26

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

FDA承诺加快对Boehringer肺部疾病药物审批

2014-12-13

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

Boehringer开发抗凝血剂解毒剂获FDA突破性药物认证

2015-02-19

12498fa0m11暂无昵称 (审核中...)

前往app查看评论内容

#Boehringer#

Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布

2013-07-19

科室
- - 订阅+
  - 更多科室
工具
服务